Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 – ...

Tumor necrosis factor (TNF)-related apoptosis-inducing ... In the first model, NOD mice received an injection of a soluble TRAIL receptor to block TRAIL function. This significantly accelerated ...

Obesity can lead to a chronic inflammatory state within the body. What drives this inflammation? Does inflammation, in turn, ...

Newly discovered oncology drugs called “DNA-encoded tri-specific T-cell engagers,” or “DTriTEs,” engage the immune system ...

Nektar Therapeutics’s NKTR share price has dipped by 5.72%, which has investors questioning if this is right time to buy.

tumor necrosis factor inhibitors, vedolizumab (Entyvio), or ustekinumab (Stelara). Of these patients, 35 received 450 mg of intravenous lusvertikimab, 50 received a 850-mg dose, and 49 received ...

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash ...